Literature DB >> 11179479

Epitope-dependent differential immunoreactivities of anti-MUC1 monoclonal antibodies in human carcinomas.

S E Baldus1, D Goergen, F G Hanisch, H P Dienes.   

Abstract

According to studies on a variety of malignant tumors from different organs MUC1 mucin antigen presents as a valuable marker of cancer progression and prognosis. During recent years, a great number of monoclonal antibodies (mabs) directed to MUC1 was generated. Their epitopes can be classified according to their position within the tandem repeat domain of the mucin and with respect to effects exerted by site-specific glycosylation. In this study, eight mabs from different clusters were selected to correlate their epitope specificity with their binding pattern in human cancer specimens. By applying an immunohistochemical ABC-peroxidase method, ten carcinomas derived from breast, pancreas, stomach and colon were characterized. A positive reaction of all mabs could be observed in the majority of the carcinomas, however, the extent of the stained tumor area varied significantly. In general, mabs M38, VA1 and BC3 exhibited the strongest staining reaction. Mab BW835 showed a similar binding intensity, especially in pancreatic and gastric carcinomas. It is tempting to speculate that the different binding patterns may reflect differences in epitope specificity. In conclusion, future immunohistochemical, immunoserological and therapeutic studies involving MUC1 antigen should prefer well-characterized and highly reactive mabs detecting defined peptide epitopes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11179479     DOI: 10.3892/ijo.18.3.507

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  2 in total

1.  A human immunoglobulin G1 antibody originating from an in vitro-selected Fab phage antibody binds avidly to tumor-associated MUC1 and is efficiently internalized.

Authors:  Paula Henderikx; Nicole Coolen-van Neer; Anita Jacobs; Edith van der Linden; Jan-Willem Arends; Jürgen Müllberg; Hennie R Hoogenboom
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

Review 2.  Advances in MUC1-Mediated Breast Cancer Immunotherapy.

Authors:  Zhifeng Li; Dazhuang Yang; Ting Guo; Mei Lin
Journal:  Biomolecules       Date:  2022-07-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.